当前位置: 首页 >> 检索结果
221. The Effect of Frailty on the Efficacy and Safety of Intensive Blood Pressure Control: A Post Hoc Analysis of the SPRINT Trial.
作者: Zhiyan Wang.;Xin Du.;Chang Hua.;Wenjie Li.;Hao Zhang.;Xinru Liu.;Yufeng Wang.;Chao Jiang.;Jiakun Guo.;Qiang Lv.;Craig S Anderson.;Jianzeng Dong.;Changsheng Ma.
来源: Circulation. 2023年148卷7期565-574页
Frailty is associated with an increased risk of all-cause death and cardiovascular events. However, it is uncertain whether frailty modifies the efficacy and safety of intensive blood pressure control.
222. Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial.
作者: Scott D Solomon.;Charles J Lowenstein.;Ankeet S Bhatt.;Alexander Peikert.;Orly Vardeny.;Mikhail N Kosiborod.;Jeffrey S Berger.;Harmony R Reynolds.;Stephanie Mavromichalis.;Anya Barytol.;Andrew D Althouse.;James F Luther.;Eric S Leifer.;Andrei L Kindzelski.;Mary Cushman.;Michelle N Gong.;Lucy Z Kornblith.;Pooja Khatri.;Keri S Kim.;Lisa Baumann Kreuziger.;Lana Wahid.;Bridget-Anne Kirwan.;Mark W Geraci.;Matthew D Neal.;Judith S Hochman.; .
来源: Circulation. 2023年148卷5期381-390页
COVID-19 has been associated with endothelial injury, resultant microvascular inflammation and thrombosis. Activated endothelial cells release and express P-selectin and von Willebrand factor, both of which are elevated in severe COVID-19 and may be implicated in the disease pathophysiology. We hypothesized that crizanlizumab, a humanized monoclonal antibody to P-selectin, would reduce morbidity and death in patients hospitalized for COVID-19.
223. Predicting Stroke in Heart Failure and Preserved Ejection Fraction Without Atrial Fibrillation.
作者: Toru Kondo.;Karola S Jering.;Pardeep S Jhund.;Inder S Anand.;Akshay S Desai.;Carolyn S P Lam.;Aldo P Maggioni.;Felipe A Martinez.;Milton Packer.;Mark C Petrie.;Marc A Pfeffer.;Margaret M Redfield.;Jean L Rouleau.;Dirk J van Veldhuisen.;Faiez Zannad.;Michael R Zile.;Scott D Solomon.;John J V McMurray.
来源: Circ Heart Fail. 2023年16卷7期e010377页
The rate of stroke in patients with heart failure (HF) and preserved ejection fraction but without atrial fibrillation (AF), is uncertain as is whether it is possible to reliably predict the risk of stroke in these patients.
224. Cardiac Magnetic Resonance Imaging Versus Invasive-Based Strategies in Patients With Chest Pain and Detectable to Mildly Elevated Serum Troponin: A Randomized Clinical Trial.
作者: Chadwick D Miller.;Simon A Mahler.;Anna C Snavely.;Subha V Raman.;Jeffrey M Caterino.;Carol L Clark.;Alan E Jones.;Michael E Hall.;Lauren E Koehler.;James F Lovato.;Brian C Hiestand.;Jason P Stopyra.;Carolyn J Park.;Sujethra Vasu.;Michael A Kutcher.;W Gregory Hundley.
来源: Circ Cardiovasc Imaging. 2023年16卷6期e015063页
The optimal diagnostic strategy for patients with chest pain and detectable to mildly elevated serum troponin is not known. The objective was to compare clinical outcomes among an early decision for a noninvasive versus an invasive-based care pathway.
225. Left Atrial Function Predicts Atrial Arrhythmia Recurrence Following Ablation of Long-Standing Persistent Atrial Fibrillation.
作者: Habib Rehman Khan.;Haci Yakup Yakupoglu.;Ines Kralj-Hans.;Shouvik Haldar.;Toufan Bahrami.;Jonathan Clague.;Anthony De Souza.;Wajid Hussain.;Julian Jarman.;David Gareth Jones.;Tushar Salukhe.;Vias Markides.;Dhiraj Gupta.;Rajdeep Khattar.;Tom Wong.; .
来源: Circ Cardiovasc Imaging. 2023年16卷6期e015352页
Left atrial (LA) function following catheter or surgical ablation of de-novo long-standing persistent atrial fibrillation (AF) and its impact on AF recurrence was studied in patients participating in the CASA-AF trial (Catheter Ablation vs. Thoracoscopic Surgical Ablation in Long Standing Persistent Atrial Fibrillation).
226. Prediction of Shock-Refractory Ventricular Fibrillation During Resuscitation of Out-of-Hospital Cardiac Arrest.
作者: Jason Coult.;Betty Y Yang.;Heemun Kwok.;J Nathan Kutz.;Patrick M Boyle.;Jennifer Blackwood.;Thomas D Rea.;Peter J Kudenchuk.
来源: Circulation. 2023年148卷4期327-335页
Out-of-hospital cardiac arrest due to shock-refractory ventricular fibrillation (VF) is associated with relatively poor survival. The ability to predict refractory VF (requiring ≥3 shocks) in advance of repeated shock failure could enable preemptive targeted interventions aimed at improving outcome, such as earlier administration of antiarrhythmics, reconsideration of epinephrine use or dosage, changes in shock delivery strategy, or expedited invasive treatments.
227. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
作者: Stephen J Greene.;Eric J Velazquez.;Kevin J Anstrom.;Robert M Clare.;Tracy A DeWald.;Mitchell A Psotka.;Andrew P Ambrosy.;Gerin R Stevens.;John J Rommel.;Tamas Alexy.;Fassil Ketema.;Dong-Yun Kim.;Patrice Desvigne-Nickens.;Bertram Pitt.;Eric L Eisenstein.;Robert J Mentz.; .
来源: Circulation. 2023年148卷2期124-134页
Loop diuretics are a primary therapy for the symptomatic treatment of heart failure (HF), but whether torsemide improves patient symptoms and quality of life better than furosemide remains unknown. As prespecified secondary end points, the TRANSFORM-HF trial (Torsemide Comparison With Furosemide for Management of Heart Failure) compared the effect of torsemide versus furosemide on patient-reported outcomes among patients with HF.
228. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.
作者: Michael E Nassif.;Sheryl L Windsor.;Kensey Gosch.;Barry A Borlaug.;Mansoor Husain.;Silvio E Inzucchi.;Dalane W Kitzman.;Darren K McGuire.;Bertram Pitt.;Benjamin M Scirica.;Sanjiv J Shah.;Guillermo Umpierrez.;Bethany A Austin.;Sumant Lamba.;Taiyeb Khumri.;Kavita Sharma.;Mikhail N Kosiborod.
来源: Circ Heart Fail. 2023年16卷7期e009837页
Patients with heart failure (HF) have a high burden of symptoms and physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 (sodium-glucose cotransporter-2) inhibitors on these outcomes vary across the full range of EF remains unclear.
229. Reach Out Emergency Department: A Randomized Factorial Trial to Determine the Optimal Mobile Health Components to Reduce Blood Pressure.
作者: Lesli E Skolarus.;Mackenzie Dinh.;Kelley M Kidwell.;Chun Chieh Lin.;Lorraine R Buis.;Devin L Brown.;Rockefeller Oteng.;Michael Giacalone.;Kimberly Warden.;Deborah E Trimble.;Candace Whitfield.;Zahera Farhan.;Adam Flood.;Dominic Borgialli.;Sacha Montas.;Michael Jaggi.;William J Meurer.
来源: Circ Cardiovasc Qual Outcomes. 2023年16卷5期e009606页
Mobile health (mHealth) strategies initiated in safety-net Emergency Departments may be one approach to address the US hypertension epidemic, but the optimal mHealth components or dose are unknown.
230. Effects of Atrioventricular Optimization on Left Ventricular Reverse Remodeling With Cardiac Resynchronization Therapy: Results of the SMART-CRT Trial.
作者: Michael R Gold.;Kenneth A Ellenbogen.;Christophe Leclercq.;Jonathan Lowy.;Seth J Rials.;Morio Shoda.;Gery Tomassoni.;Ziad Issa.;Jean-Francois Sarrazin.;John M Jennings.;Devi G Nair.;Nicholas Wold.;Patrick Yong.;Michelle M Harbin.;Kenneth M Stein.;Angelo Auricchio.
来源: Circ Arrhythm Electrophysiol. 2023年16卷6期e011714页
The role of atrioventricular optimization (AVO) to improve cardiac resynchronization therapy outcomes remains controversial. Previous post hoc analyses of a multicenter trial showed that measures of electrical dyssynchrony (right ventricular-left ventricular [LV] or LV electrical delay durations) are associated with patients who benefit from AVO.
231. Fibrotic Plaque and Microvascular Dysfunction Predict Early Cardiac Allograft Vasculopathy Progression After Heart Transplantation: The Early Post Transplant Cardiac Allograft Vasculopathy Study.
作者: Sharon Chih.;Aun Yeong Chong.;Vladimír Džavík.;Derek Y So.;Natasha Aleksova.;George A Wells.;Jordan Bernick.;Christopher B Overgaard.;Ellamae Stadnick.;Lisa M Mielniczuk.;Rob S B Beanlands.;Heather J Ross.
来源: Circ Heart Fail. 2023年16卷6期e010173页
Early cardiac allograft vasculopathy (CAV) prognostication is needed to improve long-term outcomes after heart transplantation. We characterized first year posttransplant coronary anatomic-physiologic alterations to determine predictors of early CAV progression.
232. Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial.
作者: Benjamin Z Galper.;Khaja M Chinnakondepalli.;Kaijun Wang.;Elizabeth A Magnuson.;Michael Lu.;Vinod H Thourani.;Susheel Kodali.;Raj Makkar.;Howard C Herrmann.;Samir Kapadia.;Mathew Williams.;John Webb.;Craig R Smith.;Michael J Mack.;Martin B Leon.;David J Cohen.; .
来源: Circulation. 2023年147卷21期1594-1605页
In patients with severe symptomatic aortic stenosis at low surgical risk, transfemoral transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve has been shown to reduce the composite of death, stroke, or rehospitalization at 2-year follow-up compared with surgical aortic valve replacement (SAVR). Whether TAVR is cost-effective compared with SAVR for low-risk patients remains uncertain.
233. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial.
作者: Gregory Piazza.;Alex C Spyropoulos.;Judith Hsia.;Mark Goldin.;William J Towner.;Alan S Go.;Todd M Bull.;Stephen Weng.;Concetta Lipardi.;Elliot S Barnathan.;Marc P Bonaca.; .
来源: Circulation. 2023年147卷25期1891-1901页
COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor, we conducted the PREVENT-HD double-blind, placebo-controlled randomized trial (A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19] Infection).
234. Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial.
作者: Karola S Jering.;Brian L Claggett.;Marc A Pfeffer.;Christopher B Granger.;Lars Køber.;Eldrin F Lewis.;Aldo P Maggioni.;Douglas L Mann.;John J V McMurray.;Margaret F Prescott.;Jean L Rouleau.;Scott D Solomon.;Phillippe Gabriel Steg.;Dirk von Lewinski.;Eugene Braunwald.
来源: Circ Heart Fail. 2023年16卷5期e010259页
NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a potent predictor of death and heart failure (HF) across multiple populations. We evaluated the prognostic importance of NT-proBNP in patients with acute myocardial infarction (MI) complicated by left ventricular systolic dysfunction, pulmonary congestion, or both and ≥1 of 8 risk-augmenting factors enrolled in the PARADISE-MI trial (Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction).
235. Empagliflozin Improves Left Atrial Strain in Patients With Type 2 Diabetes: Data From a Randomized, Placebo-Controlled Study.
作者: Kirsten Thiele.;Matthias Rau.;Julian Grebe.;Niels-Ulrik Korbinian Hartmann.;Ertunc Altiok.;Michael Böhm.;András P Keszei.;Nikolaus Marx.;Michael Lehrke.
来源: Circ Cardiovasc Imaging. 2023年16卷4期e015176页 236. Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
作者: Moritz J Hundertmark.;Amanda Adler.;Charalambos Antoniades.;Ruth Coleman.;Julian L Griffin.;Rury R Holman.;Hanan Lamlum.;Jisoo Lee.;Daniel Massey.;Jack J J J Miller.;Joanne E Milton.;Shveta Monga.;Ferenc E Mózes.;Areesha Nazeer.;Betty Raman.;Oliver Rider.;Christopher T Rodgers.;Ladislav Valkovič.;Eleanor Wicks.;Masliza Mahmod.;Stefan Neubauer.
来源: Circulation. 2023年147卷22期1654-1669页
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of action remains elusive. Derangements in myocardial energy metabolism are detectable in all HF phenotypes, and it was proposed that SGLT2i may improve energy production. The authors aimed to investigate whether treatment with empagliflozin leads to changes in myocardial energetics, serum metabolomics, and cardiorespiratory fitness.
237. Letter by Kambic et al Regarding Article, "A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure With Preserved Ejection Fraction".238. Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study.
作者: Lucas Yixi Xing.;Søren Zöga Diederichsen.;Søren Højberg.;Derk W Krieger.;Claus Graff.;Ruth Frikke-Schmidt.;Morten S Olesen.;Axel Brandes.;Lars Køber.;Ketil Jørgen Haugan.;Jesper Hastrup Svendsen.
来源: Circulation. 2023年147卷24期1788-1797页
Research suggests NT-proBNP (N-terminal pro-B-type natriuretic peptide) to be a strong predictor of incident atrial fibrillation (AF) and stroke. However, its utility in AF screening remains unknown. The aim of this study was to investigate NT-proBNP as a potential marker for screening efficacy with respect to AF yield and stroke prevention.
239. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
作者: Gerasimos Filippatos.;Piotr Ponikowski.;Dimitrios Farmakis.;Stefan D Anker.;Javed Butler.;Vincent Fabien.;Bridget-Anne Kirwan.;Iain C Macdougall.;Marco Metra.;Giuseppe Rosano.;Frank Ruschitzka.;Peter van der Meer.;Sandra Wächter.;Ewa A Jankowska.; .
来源: Circulation. 2023年147卷22期1640-1653页
Iron deficiency, with or without anemia, is an adverse prognostic factor in heart failure (HF). In AFFIRM-AHF (a randomized, double-blind placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalizations and mortality in iron-deficient subjects admitted for acute heart failure), intravenous ferric carboxymaltose (FCM), although having no significant effect on the primary end point, reduced the risk of HF hospitalization (hHF) and improved quality of life versus placebo in iron-deficient patients stabilized after an acute HF (AHF) episode. These prespecified AFFIRM-AHF subanalyses explored the association between hemoglobin levels and FCM treatment effects.
240. Angina After Percutaneous Coronary Intervention: Patient and Procedural Predictors.
作者: Damien Collison.;Samuel Copt.;Takuya Mizukami.;Carlos Collet.;Ruth McLaren.;Matthaios Didagelos.;Muhammad Aetesam-Ur-Rahman.;Peter McCartney.;Thomas J Ford.;Mitchell Lindsay.;Aadil Shaukat.;Paul Rocchiccioli.;Richard Brogan.;Stuart Watkins.;Margaret McEntegart.;Richard Good.;Keith Robertson.;Patrick O'Boyle.;Andrew Davie.;Adnan Khan.;Stuart Hood.;Hany Eteiba.;Colin Berry.;Keith G Oldroyd.
来源: Circ Cardiovasc Interv. 2023年16卷4期e012511页
Twenty percent to 40% of patients are affected by angina after percutaneous coronary intervention (PCI), which is associated with anxiety, depression, impaired physical function, and reduced quality of life. Understanding patient and procedural factors associated with post-PCI angina may inform alternative approaches to treatment.
|